Light AI appoints Luna as CEO

Executive Summary

• Light AI Inc. appointed John R. Luna as Chief Executive Officer, effective Jan. 19, 2026, succeeding founder Peter Whitehead, who transitions to Chief Innovation Officer.
• The company reported $6.5 million in cash and investments as of Dec. 31, 2025, with a financial runway extending past Q3 2026 to support its strategic shift from the development phase to regulatory and commercialization initiatives.
• To preserve capital during this transition, CFO George Reznik is stepping down and will be replaced by a part-time fractional CFO, while the company anticipates a significant reduction in R&D and operating expenses.

Key Details

• CEO Appointment: John R. Luna appointed as CEO effective Jan. 19, 2026, with a strategic focus on regulatory authorization, evidence generation, and early commercialization of the AI imaging platform.
• Leadership Transition: Founder Peter Whitehead transitions to Chief Innovation Officer to continue leading the medical diagnostic offering and intellectual property expansion.
• CFO Transition: CFO George Reznik is transitioning out of the company; a part-time fractional CFO will be engaged to support financial runway preservation initiatives.
• Financial Position & Runway: Total cash and investments of approximately $6.5 million as of Dec. 31, 2025; sufficient capital anticipated to fund regulatory/commercialization initiatives and operations beyond Q3 2026.
• Expense Restructuring: Anticipates a significant reduction in research and development and other operating expenses, offset by increased investment in regulatory and commercialization initiatives.
• CEO Background: Luna brings 30+ years of experience in healthcare technology and AI; previously served as executive adviser to EssilorLuxottica (guiding FDA 510(k) clearance for Nuance hearing aid software) and as CEO of a public medtech company (launching the first FDA-cleared self-fitting OTC hearing aid).
• Technology & Validation: AI smartphone imaging platform for rapid disease screening (starting with Strep A, expanding to COVID-19, eye, and skin); pre-FDA validation demonstrated 96.57% accuracy and 100% negative predictive value for group A streptococcus (GAS) pharyngitis.

Notable Quotes

• John R. Luna, CEO: "Light AI represents the future of diagnostics in health care -- where artificial intelligence becomes a scalable software imaging platform capable of detecting, diagnosing and managing disease on a global scale... By aligning disciplined regulatory execution with capital-efficient commercialization, Light AI has the potential to fundamentally change how disease is identified and managed worldwide."
• Steven Semmelmayer, Chair of the Board: "I am excited to welcome John R. Luna as Light AI's new chief executive officer with his wealth of regulatory and commercialization experience in the medical technology industry to accelerate the capitalization of Light AI's market opportunity... I look forward to John's leadership and partnership with Peter and am very optimistic regarding the company's outlook."